Botswana Harvard AIDS Institute Partnership
15
1
5
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 15 trials
100.0%
+13.5% vs industry average
40%
6 trials in Phase 3/4
25%
2 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Primary HPV-based Cervical Cancer Screening Algorithms in Botswana
Role: collaborator
Healthy Expectancy Through Routine Antenatal STI Screening
Role: collaborator
Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana
Role: collaborator
POC HIV Testing and Early DTG Use for Infants
Role: collaborator
A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation
Role: collaborator
STI Testing to Enhance PrEP Use in Pregnancy
Role: lead
Antenatal Chlamydia Trachomatis and Neisseria Gonorrhoeae Testing to Prevent Adverse Neonatal Consequences
Role: collaborator
Mopati: A Pilot Hiv Treatment Partner Intervention In Botswana
Role: collaborator
COVID-19 Antigen Rapid Test Evaluation in Low-Prevalence Setting
Role: collaborator
Investigating the Interaction Between Two Long-acting Reversible Methods of Contraception and Dolutegravir, a Treatment for HIV
Role: lead
Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2
Role: lead
Botswana Combination Prevention Project
Role: collaborator
Feasibility and Accuracy of Nanosensor-based Cancer Diagnosis at the Point-of-care (Chedza)
Role: collaborator
The Lived Experience of Participants in an African Randomised Trial
Role: collaborator
Potlako: A Programmatic Intervention to Improve Access to Timely Oncology Care
Role: collaborator
All 15 trials loaded